Valuation: Bolt Biotherapeutics, Inc.

Market Cap 7.71M 6.87M 6.35M 5.78M 10.89M 732M 11.06M 76.47M 30.01M 382M 28.92M 28.3M 1.22B P/E 2026 *
-0.17x
P/E 2027 * -0.2x
Enterprise Value 7.71M 6.87M 6.35M 5.78M 10.89M 732M 11.06M 76.47M 30.01M 382M 28.92M 28.3M 1.22B EV / Sales 2026 *
38.5x
EV / Sales 2027 * 2.2x
Free-Float
96.53%
Yield 2026 *
-
Yield 2027 * -
1 day-5.66%
1 week-2.68%
Current month+8.70%
1 month+19.58%
3 months-9.50%
6 months-15.43%
Current year-26.85%
1 week 3.76
Extreme 3.76
4.68
1 month 3.38
Extreme 3.38
4.68
Current year 3.1
Extreme 3.1
7.2
1 year 3.1
Extreme 3.1
7.2
3 years 3.1
Extreme 3.1
31.2
5 years 3.1
Extreme 3.1
280.6
10 years 3.1
Extreme 3.1
861.4
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 15/05/2024
Chief Executive Officer 55 15/05/2024
Chief Operating Officer 61 15/05/2024
Director TitleAgeSince
Director/Board Member 64 01/12/2020
Director/Board Member 55 15/05/2024
Chairman 56 04/09/2024
Date Insider Type Main position Quantity % Market Cap. Importance
18/09/26 Sell

Chief Operating Officer

-6,850 0.3556%
18/09/26 Sell

Controller/Auditor

-4,077 0.2116%
18/09/26 Sell

Chief Executive Officer

-9,132 0.4741%
Change 5-day change 1-year change 3-year change Capi.($)
-5.66%-2.68%-30.44%-80.00% 7.71M
-6.60%-8.56%+49.38%+63.51% 65B
+0.03%+5.56%+9.10%+69.05% 51.2B
-4.09%-0.11%+2.22%+53.15% 51.19B
-1.53%+2.70%+30.48%+34.12% 43.93B
-1.34%+4.12%+16.64%+115.13% 41.96B
-5.97%-6.22%+228.95%+454.22% 38.14B
+6.53%+8.02%+16.40%+53.41% 33.24B
-0.90%-10.49%+37.09%-3.70% 25.2B
-1.07%+2.33%+19.43%+9.98% 22.5B
Average -2.06%-0.58%+37.92%+76.89% 37.24B
Weighted average by Cap. -2.20%-0.50%+44.25%+96.53%

Financials

2026 *2027 *
Net sales 200K 178K 165K 150K 283K 18.99M 287K 1.98M 779K 9.9M 751K 735K 31.57M 3.5M 3.12M 2.89M 2.63M 4.94M 332M 5.03M 34.73M 13.63M 173M 13.13M 12.85M 552M
Net income -47.4M -42.27M -39.08M -35.58M -66.96M -4.5B -68.06M -470M -185M -2.35B -178M -174M -7.48B -47.5M -42.36M -39.16M -35.65M -67.1M -4.51B -68.21M -471M -185M -2.35B -178M -174M -7.5B
Net Debt - -
Projected Income Statement - Annual - Bolt Biotherapeutics, Inc.
Logo Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Employees
23
Date Price Change Volume
16/10/26 $4.000 -5.66% 10,118
15/10/26 $4.240 +6.53% 9,255
14/10/26 $3.980 -7.12% 31,070
13/10/26 $4.285 +1.06% 12,826
12/10/26 $4.240 +3.16% 28,728
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Bolt Biotherapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.000USD
Average target price
29.00USD
Spread / Average Target
+625.00%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Bolt Biotherapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. BOLT Stock